Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Choueiri on the Research With Immunotherapy in RCC

October 14th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses research involving immunotherapy regimens for patients with renal cell carcinoma (RCC).

Dr. Inman Discusses the Role of Chemotherapy in Bladder Cancer

October 13th 2017

Brant Inman, MD, surgical oncologist, urologic oncologist, Duke Cancer Center, discusses the role of chemotherapy in bladder cancer.

Revised Guidelines Helping to Advance Kidney Cancer Care

October 13th 2017

Robert G. Uzzo, MD, discusses recent guidelines that have impacted clinical practice and ongoing biomarker research in the field of kidney cancer.

Dr. Pal on the CheckMate-214 and CABOSUN Studies in RCC

October 13th 2017

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope in Duarte, California, discusses the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

Novel Immunotherapy Approaches Moving Through RCC Pipeline

October 12th 2017

Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.

Dr. Lalani on a Study of Neutrophil-Lymphocyte Ratio in RCC

October 10th 2017

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

Dr. Choueiri on the Role of Cabozantinib in RCC

October 10th 2017

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

Immunotherapy Agents Leading Advancements in Metastatic Bladder Cancer

October 10th 2017

The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.

Dr. Bosse on the Safety Profile With Radium-223 Plus VEGF in RCC

October 10th 2017

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

Control of Non-Muscle Invasive Bladder Cancer Recurrence With TURBT and Beyond

October 10th 2017

The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.

Expert Urges for a More Multidisciplinary Approach to Bladder Cancer Care

October 6th 2017

Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.

Dr. Comperat on the Treatment Strategy for Neuroendocrine Tumors

October 6th 2017

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer

October 6th 2017

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

IMRT Linked With Low Rates of Pelvic Recurrence in Bladder Cancer

October 6th 2017

Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence

New Bladder Cancer Monitor Allows Non-invasive Routine Surveillance of NMIBC

October 6th 2017

A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.

Chemotherapy Retains Vital Role in Bladder Cancer Care

October 6th 2017

Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.

Dr. Konety on Guidelines for the Management of Bladder Cancer

October 6th 2017

Badrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.

Dr. De Santis on the Future Treatment Landscape for Bladder Cancer

October 6th 2017

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

Exploring the Role of Chemotherapy and Immunotherapy Combos in Urothelial Carcinoma

October 5th 2017

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

Pembrolizumab Is Safe and Effective in Cisplatin-Ineligible Advanced Urothelial Carcinoma

October 5th 2017

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.